INCAGN2390 (anti-TIM-3)
Melanoma, SCCHN
Phase 2Partnered - Incyte
Key Facts
About Agenus
Agenus is a mission-driven biotech focused on developing novel immunotherapies for cancer, particularly for patients unresponsive to current treatments. Its primary achievement is the development of botensilimab, a next-generation Fc-enhanced CTLA-4 antibody, which in combination with balstilimab (anti-PD-1) has shown compelling clinical activity in microsatellite stable (MSS) colorectal cancer, a major unmet need. The company's strategy centers on advancing this lead combination through a pivotal Phase 3 trial while leveraging strategic partnerships and its adjuvant royalty stream to fund operations. Agenus aims to broaden the population of cancer patients who can benefit from immunotherapy.
View full company profileOther Melanoma, SCCHN Drugs
| Drug | Company | Phase |
|---|---|---|
| INCAGN2385 (anti-LAG-3) | Agenus | Phase 2 |